Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Revenue as a part of R&D spending for select cancer drugs 2017

This statistic shows the revenue of select cancer drugs as a share of their research and development (R&D) spending, as of 2017. As of that year, Alexion Pharmaceuticals' drug Eculizumab had a revenue equal to 1588.5 percent of its R&D costs.

Revenue as a percentage of R&D spending for select cancer drugs on the market as of 2017

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

November 2017

Region

United States

Survey time period

as of November 2017

Supplementary notes

This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA).
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Oncology"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.